William Blair Has Bullish Forecast for Medpace Q1 Earnings

Medpace Holdings, Inc. (NASDAQ:MEDP) – Investment analysts at William Blair boosted their Q1 2025 earnings per share estimates for shares of Medpace in a note issued to investors on Tuesday, February 11th. William Blair analyst M. Smock now forecasts that the company will earn $3.11 per share for the quarter, up from their previous forecast of $2.92. William Blair has a “Outperform” rating on the stock. The consensus estimate for Medpace’s current full-year earnings is $11.93 per share. William Blair also issued estimates for Medpace’s Q2 2025 earnings at $3.09 EPS and FY2026 earnings at $13.89 EPS.

Several other research analysts have also recently issued reports on MEDP. TD Cowen dropped their price objective on Medpace from $413.00 to $372.00 and set a “buy” rating on the stock in a research note on Wednesday, October 23rd. Baird R W lowered Medpace from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 23rd. Finally, Robert W. Baird lifted their price objective on Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a report on Monday, January 27th. Seven analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $381.44.

Medpace Price Performance

Shares of MEDP stock opened at $342.41 on Friday. The company’s 50-day simple moving average is $343.70 and its two-hundred day simple moving average is $348.88. Medpace has a one year low of $302.01 and a one year high of $459.77. The company has a market capitalization of $10.64 billion, a P/E ratio of 29.98, a P/E/G ratio of 1.85 and a beta of 1.36.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings results on Monday, February 10th. The company reported $3.67 EPS for the quarter, topping the consensus estimate of $2.96 by $0.71. Medpace had a net margin of 17.66% and a return on equity of 50.87%.

Hedge Funds Weigh In On Medpace

A number of large investors have recently added to or reduced their stakes in the company. Invesco Ltd. boosted its holdings in shares of Medpace by 91.8% in the 4th quarter. Invesco Ltd. now owns 1,084,753 shares of the company’s stock valued at $360,387,000 after buying an additional 519,186 shares in the last quarter. Proficio Capital Partners LLC boosted its stake in Medpace by 34,497.4% in the fourth quarter. Proficio Capital Partners LLC now owns 242,528 shares of the company’s stock valued at $80,575,000 after acquiring an additional 241,827 shares in the last quarter. Raymond James Financial Inc. purchased a new position in Medpace in the fourth quarter worth $78,144,000. Norges Bank purchased a new position in Medpace in the fourth quarter worth $69,859,000. Finally, Iron Triangle Partners LP acquired a new position in shares of Medpace during the third quarter worth $64,371,000. 77.98% of the stock is currently owned by institutional investors.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.